---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-24-000120"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:20:14.981938+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed

## Summary
- Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).
- Biologics & drug delivery revenue $4.4M (+27%); capital equipment revenue $0.8M (+133%).
- Gross margin 60% vs 57% YoY; operating expenses $10M (up from $8.2M) on higher personnel and development costs.
- Cash $21.6M; fully repaid $10M convertible note leaving no debt; operational cash burn cut 33% to $1.2M.
- Activated 5 new centers in Q3 (19 YTD, ~3x historic rate); FY 2024 revenue outlook held at $30-33M.

## SEC filing metadata
- accession: 0001285550-24-000120
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000120/0001285550-24-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000120/clpt-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-24-000120
- JSON: https://secwatch.observer/filing/0001285550-24-000120.json
- Plain text: https://secwatch.observer/filing/0001285550-24-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.